Lascco
Company Team Projects Media Contact
         
 
 
NEWS

• 02.05.2019: Results of the first CAL02 clinical trial published in The Lancet Infectious Diseases

• 04.04.2019: Combioxin to present at the Therapeutics pipeline corner session at the ECCMID 2019 in Amsterdam

• 24.10.2018: Combioxin selected for oral presentation on the results of the first CAL02 clinical trial at the ESICM Annual Congress 2018 in Paris

• 21.08.2018: Combioxin invited to present CAL02's clinical data at the FDA's Workshop on the Development of Non-Traditional Therapies for Bacterial Infections on Aug 21-22, 2018

• 17.04.2018: Positive Topline Results from First-in-human Trial with CAL02 in the treatment of severe pneumonia

• 10.10.2017: Independent Data Monitoring Committee concluded that CAL02 showed positive safety profile at high dose in the CAL02-001 clinical trial

• 15.03.2017: Oral presentation of interim results from the CAL02-001 clinical trial at ECCMID 2017

• 23.03.2016: Combioxin announces first patient enrolled in CAL02 First-in-human clinical trial

• 02.01.2015: Positive preclinical efficacy data for CAL02 published in Nature Biotechnology

 

 
 
MEDIA
 

• 13.05.2017: De la science au produit - Bilan

• 15.02.2017: Prof Laterre talks about CAL02 in his ICU - broadcasted on 3sat - Nano

• 04.11.2014: Une nouvelle voie pour lutter contre la résistance aux antibiotiques - Le Temps

• 29.10.2014 : Le long chemin vers la therapy - L'AGEFI

• 12.09.2014: Au-delà des antibiotiques - vaincre les résistances des bactéries - Le Temps